Efficacy of GLP-1 analog to achieve metabolic control and correction of body weight in patients with type 2 diabetes mellitus
https://doi.org/10.20538/1682-0363-2011-6-114-119
Abstract
Obesity associated with the enhanced risk of cardiovascular disorders plays a key role in the evolvement and progression of type 2 diabetes mellitus (DM2). Incretin mimetics are the sole class of hypoglycemic agents that not only effectively correct hyperglycemia but also reduce body weight. Exenatide (Byetta, Eli Lilly, USA) is the first drug of this class approved for the use as monotherapy. This paper presents data of clinical studies and owns data on the effectiveness of the drug Byetta in achieving metabolic control and weight correction in patients with type 2 diabetes.
About the Authors
T. V. Saprina
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
T. K. Gudkova
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
V. A. Stolyarova
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
S. Yu. Martynova
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
N. G. Dudarkova
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
T. G. Yaroshevskaya
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
Yu. A. Kabirova
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
O. A. Pavlenko
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
I. N. Vorozhtsova
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
References
1. Аметов А.С. Достижение двух целей терапии: контроль гликемии и снижение массы тела//Рос. мед. журн. 2006. Т. 17, № 24 (363). С. 2.
2. Викулова О.К., Шестакова M.B. Новые показания к терапии эксенатидом у больных сахарным диабетом 2 типа с ожирением//Сахарный диабет. 2010. № 3. С. 98-101.
3. Шестакова M.B., Викулова О.К. Современные возможности фармакотерапии сахарного диабета 2 типа при помощи аналогов глюкагоноподобного пептида-1 (ГПП-1)//Сахарный диабет. 2007. № 1. C. 9-15.
4. Apovian C.M., Bergenstal R.M., Cuddihy R.M. et al. Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes//The American Journal of Medicine. 2010. № 123 (5). P. 9-l7.
5. Barnett A.H., Burger J., Johns D., Brodows R. et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period crossover no inferiority trial//Clinical Therapeutics. 2007. № 29. С. 2333-2348.
6. Bunck M.C., Diamant M., Eliasson B. et al. Exenatide affected circulating cardiovascular risk biomarkers independently of changes in body composition//Diabetes Care publish ahead of print, published online April 27, 2010, Available at http://care.diabetesjournals.org.
7. Buse J., Henry R., Han J. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes//Diabetes Care. 2004. № 27 (11). P. 2628-2635.
8. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo//J. Clin. Endocnnol. Metab. 1995. № 80. P. 952-957.
9. DeFronzo R., Ratner R., Han J. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes//Diabetes Care. 2005. № 28 (5). P. 1092-1100.
10. Heine R.J., Van Gaal L.F., Johns D. et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial//Ann. Intern. Med. 2005. № 143 (8). P. 559-569.
11. Holst J.J. GLP-1 receptor agonists for the treatment of diabetes//Int. Diabetes. Monitor. 2005. № 17 (6). P. 11-18.
12. Kendall D.M., Riddle M.C., Rosenstock J. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea//Diabetes Care. 2005. № 28 (5). P. 1083-1091.
13. Klonoff D.C., Buse J.В., Nielsen L.L. et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years//Current Medical Research and Opinion. 2008. № 24 (1). P. 275-286.
14. Moretto T.J., Milton D.R., Ridge T.D. et al. Efficacy and Tolerability of Exenatide Monotherapy Over24 Weeks in Antidiabetic Drug-Naive Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study//Clinical Therapeutics. 2008. № 30 (8). P. 1448-1460.
15. Nauck M.A., Duran S., Kim D. et al. A comparison of a twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study//Diabetologia. 2007. № 50. P. 259-267.
16. Nielsen L.L., Young A.A., Parkers D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes//Regul. Rept. 2004. № 117. P. 77-88.
17. Prevalence of Diabetes Worldwide: Country and Regional Data. World Health Organization. Available from: http://www.who.int/diabetes/facts/world_figures/
18. Turner R.C., Cull C.A., Frighi V., Holman R.R. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: prospective requirement for multiple therapies (UKPDS 49) // JAMA. 1999. № 281. P. 2005-2012.
19. Zinman В., Hoogwerf B.J., Garcia S.D. et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes//Ann. Intern. Med. 2007. № 146. P. 477-485.
Review
For citations:
Saprina T.V., Gudkova T.K., Stolyarova V.A., Martynova S.Yu., Dudarkova N.G., Yaroshevskaya T.G., Kabirova Yu.A., Pavlenko O.A., Vorozhtsova I.N. Efficacy of GLP-1 analog to achieve metabolic control and correction of body weight in patients with type 2 diabetes mellitus. Bulletin of Siberian Medicine. 2011;10(6):114-119. (In Russ.) https://doi.org/10.20538/1682-0363-2011-6-114-119
Views:
508
Email this article 